This is a method for identifying single nucleotide polymorphisms (GALNT14 genotypes) of a target nucleic acid for predicting whether a patient suffering from HCC will respond to combination chemotherapy. Accordingly, physicians can decide whether the HCC patients should receive chemotherapyTACE. This method could also predict prognosis in multiple gastrointestinal cancers.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.